title: American Society of Clinical Oncology 2013: summary of scientific advancements in gynecologic cancer.
abstract: The American Society of Clinical Oncology (ASCO) meeting was held in Chicago, Ill, from May 31, 2013, to June 4, 2013, and focused on "Building Bridges to Conquer Cancer." An estimated 25,500 oncology professionals, with a broad range of interests, attended the meeting. Cervical cancer, a gynecologic malignancy with a significant global burden, was prominently featured at this year's meeting. In a mark of exemplary scientific accomplishment within our specialty, 2 of the 5 general session plenaries investigated advancements in cervical cancer care, extending from improved screening to treatment of metastatic disease. This was followed by the presentation of several important phase 2 and 3 clinical trials in the Gynecologic Oncology Tract, focusing on cervical, ovarian, uterine, and breast cancer, which will be discussed in this report.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, Orange, CA.
authors.forename: Ramez N
authors.initials: RN
authors.lastname: Eskander
authors.forename: Krishnansu S
authors.initials: KS
authors.lastname: Tewari
mesh_terms: D019342:Acetic Acid; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality; D005260:Female; D006176:Gynecology / Q000639:trends*; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D013629:Tamoxifen / Q000008:administration & dosage; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D000068258:Bevacizumab; D019342:Acetic Acid